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CXCR7 was recently characterized as an alternative recep-
tor for the chemokine CXCL12/SDF-1, previously thought
to bind and signal exclusively through CXCR4. We recently
identified CXCR7 as a key cellular factor in the endothelial
cell (EC) dysfunction associated with KSHV infection.
CXCL12 signaling is critically associated with tumor
growth, angiogenesis and metastasis in several diverse
tumors and is one of the most studied chemokine/chemo-
kine receptor interactions in cancer systems. The tumori-
genic activity of the CXCL12 signaling axis offers an
attractive target for therapeutic intervention in multiple
cancers including Kaposi’sS a r c o m a( K S ) .H o w e v e r ,m o s to f
the research to date was based on the assumption that
CXCR4 was the sole CXCL12 receptor, and thus focused
on the development of CXCR4-targeted treatments.
CXCR4 participates in important homeostatic functions
including hematopoiesis and mucosal immunity, while
CXCR7 is rarely expressed in normal adult cells. As a result,
CXCR7 may be a more specific chemotherapeutic target for
tumor cells and tumor-associated vasculature with fewer
adverse effects than treatments targeting CXCR4. CXCR7
is poorly studied throughout the cancer literature and
although CXCR7 expression has been found in tumor-asso-
ciated vasculature, no studies comprehensively examine the
biology of CXCR7 in EC and its implications for tumor
biology. We seek to define ther o l eo fC X C R 7 - m e d i a t e d
CXCL12 signaling in EC biology, and in the context of
KSHV infection, in order to determine potential contribu-
tions of CXCR7 signaling to KSHV-mediated EC transfor-
mation and KS tumorigenesis. We demonstrate that
CXCR7 is strongly expressed on LANA+ spindle cells in
KS biopsy tissue at all stages of tumor progression. We
further demonstrate that CXCR7 induction by KSHV in
vitro is specific to lymphatic EC lineages and occurs coinci-
dent with the acquisition of spindle morphology. Detailed
examination of CXCR7 functions in EC biology reveals
multiple roles for CXCR7 that could impact KS tumorigen-
esis, including effects on cellular proliferation, junctional
integrity, cell survival and metastatic capacity. Specifically,
we determine that CXCR7 expression results in a loss of
PECAM/CD31 expression, perturbing the formation and
maintenance of EC monolayers. Moreover, CXCR7+ EC
display significant SDF-1 dependent hypermotility, as mea-
sured via Electrical Cell-Substrate Impedence Sensing
(ECIS). We also demonstrate that SDF-1 signaling through
CXCR7 expression is enhanced in EC undergoing ancho-
rage-deprivation, affecting EC cell survival and invasion
into SDF-1 rich niches. Taken together, these results
demonstrate that CXCR7 is a novel KSHV-induced onco-
gene with the capacity to influence multiple aspects of
KS pathogenesis including tumor growth, seeding and
metastasis.
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